SNOA: Sonoma Pharmaceuticals, Inc. Company Value to Net Income

Sonoma Pharmaceuticals (SNOA) maintains a competitive moat through patents for hypochlorous acid solutions and stringent FDA requirements that shut out smaller players. The business focuses on developing dermatological acne treatments, where Microcyn technology ensures stable FCF. A portion of production and logistics has been outsourced to third-party contractors. This chart shows the market price reflects a PE multiple of -2.30.
Analytical breakdowns for Sonoma Pharmaceuticals

The stable distribution of antiseptics by Sonoma Pharmaceuticals (SNOA) is reflected in the P/E ratio history, linking market value to operational efficiency. This multiple compares the current share price to net earnings per share. This calculation determines the investment payback period via the cash flow generated by the business. Low values signal that the asset is undervalued, provided the company's debts remain manageable. This makes the instrument attractive for value analysis.